Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2023 - 2025)

Monte Rosa Therapeutics' Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 1.31% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $8.4 million, up 2.89%, while the annual FY2025 figure was $8.4 million, 2.89% up from the prior year.
  • Depreciation & Amortization (CF) reached $2.1 million in Q4 2025 per GLUE's latest filing, roughly flat from $2.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.1 million in Q2 2025 to a low of $1.2 million in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $1.9 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 64.81% in 2024, then fell 0.38% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $1.8 million in 2023, then increased by 12.99% to $2.1 million in 2024, then rose by 1.31% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Depreciation & Amortization (CF) are $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).